Nicotinic acetylcholine receptors (nAChRs) are a promising target for development of new anticancer therapies. Here we have investigated the effects of the endogenous human proteins SLURP-1 and SLURP-2, antagonists of nAChRs, on human epithelial cancer cells.
Introduction
Higher animals produce endogenous proteins from the Ly6/uPAR family, which share structural homology with snake α-neurotoxins acting on nicotinic acetylcholine receptors (nAChRs) (Loughner et al., 2016; Vasilyeva et al., 2017) . Some of these proteins, such as Lynx1 and Lypd6 in the brain, are membrane-tethered, whereas others such as the secreted Ly6/uPAR proteins SLURP-1 and SLURP-2, are secreted by epithelial tissues and probably involved in the development of a number of skin diseases including Mal de Meleda (Allan et al., 2016; Perez and Khachemoune, 2016) and psoriasis (Tsuji et al., 2003) . For example, SLURP-1 inhibits proliferation of human oral keratinocytes (Het-1A cells) via selective interactions with non-neuronal α7 type nAChRs (α7-nAChRs) (Arredondo et al., 2005; Lyukmanova et al., 2016a) , while SLURP-2 could either inhibit or promote cell growth via signalling through different subtypes of nAChRs and muscarinic acetylcholine receptors (M receptors) (Lyukmanova et al., 2016b) . Using electrophysiological recordings in Xenopus laevis oocytes, we showed that SLURP-1 is an antagonist of α7-nAChRs, while SLURP-2 inhibits α3β2 and α4β2 nAChRs but, at concentrations below 100 nM, can activate α7-nAChRs in presence of ACh (Lyukmanova et al., 2016a,b) .
Consumption of tobacco is associated with the development of small-cell and non-small-cell lung carcinomas (NSCLCs), head, neck, gastric, pancreatic, gallbladder, liver, colon, breast, cervical, urinary bladder and kidney cancers (Grando, 2014) . One of the proposed molecular mechanisms of tobacco-induced cancer development and progression involves a direct activation of α7-nAChRs by the agonist nicotine and its nitrosamine derivatives (NNK and NNN), also presented in tobacco smoke (Wessler and Kirkpatrick, 2008; Schuller, 2009; Schaal and Chellappan, 2014) . For example, NNK and NNN induced malignant transformation of keratinocytes by activation of nAChRs (Grando, 2008) . Activation of α7-nAChRs may stimulate the signalling through EGF receptors (EGFRs) and VEGF receptors, and β-adrenoceptors, which in turn activate mitogenic, antiapoptotic and proliferative pathways (Wong et al., 2007; Schaal and Chellappan, 2014) . The modulation of nAChRs could be considered a promising component of anticancer therapy (Russo et al., 2012) . Previously, it was reported that inhibition of α7-nAChRs by snake α-neurotoxins and curare reduced the growth of NSCLC tumours (Grozio et al., 2008; Zhang et al., 2016) and proliferation of human mesothelioma cells (Trombino et al., 2004) respectively. The main problems with the use of such neurotoxins for cancer therapy are irreversible binding, low specificity and high systemic toxicity.
In line with their antagonistic action, SLURPs abolished the tumorigenic effects of NNK and NNN on human keratinocytes (Grando, 2008) . We have already demonstrated the antiproliferative effect of both SLURPs on human colorectal adenocarcinoma HT-29 cells at nanomolar concentrations . As a result, we proposed that this antiproliferative activity of SLURPs could be common for cancers derived from epithelial cells. To assess this proposal, we have studied the effects of recombinant human SLURP-1 and SLURP-2 on the growth of human epidermoid carcinoma A431, breast carcinoma SKBR3, breast carcinoma MCF-7 and lung carcinoma A549 cell lines. We compared the activity of SLURPs with the activity of the high-affinity, irreversible, specific antagonist of α7-nAChRs, snake α-bungarotoxin (α-Bgtx). Our study revealed that SLURPs are natural, highly effective inhibitors of epithelial cancer cell growth. We consider that SLURPs have the potential for anticancer treatment both by themselves and in combination with other antitumor drugs.
Methods
Cell cultivation and study of the antiproliferative activity of SLURPs Human epidermoid carcinoma cells A431 (ATCC, Manassas, USA), human breast adenocarcinoma cells MCF7 (ATCC) and human lung carcinoma A549 cells (ATCC) were grown (37°C, 5% CO 2 ) in DME medium with phenol red (PanEco, Moscow, Russia), 10% fetal calf serum (FCS, Hyclone, Thermo Fisher Scientific, Waltham, USA), 2 mM L-glutamine (PanEco). Human breast adenocarcinoma cells SKBR3 (ATCC) were grown (37°C, 5% CO 2 ) in McCoy's 5A Medium (Gibco, Thermo Fisher Scientific), with 10% FCS. HT-29 cells were grown in RPMI-1640 medium, supplemented with 10% FCS. All types of cells were subcultured twice per week. The cultivation media described above (different for different cells) are abbreviated below as complete media.
To study effect of SLURPs, α-Bgtx, gefitinib, atropine, mecamylamine hydrochloride and timolol on cell growth, the cells were seeded in 96-well cell culture plates for 24 h. At these seeding densities, the majority of the cell lines used here have similar cell number duplication times (CDT, 20-27 h, Table 1 ). Thereafter, SLURP-1 or SLURP-2 (dissolved in 100% DMSO) or aqueous solutions of gefitinib, atropine, mecamylamine, timolol or α-Bgtx were added to cells at concentrations ranging from 0.1 pM to 100 μM and incubated during 24 h in a complete medium at 37°C, 5% CO 2 . Cells without addition of any compounds were used as a control. The highest final concentration of DMSO in the wells was 0.1% and this concentration did not affect cell growth. For co-application of SLURPs with different inhibitors, A431 cells were pre-incubated with gefitinib (10 nM), atropine (10 nM or 1 μM), mecamylamine (10 nM or 10 μM), timolol (10 nM) or α-Bgtx (10 nM) for 30 min and rinsed twice with a complete medium. Then, SLURP-1 or SLURP-2 (1 nM) and the corresponding inhibitor (the same concentration as in the pre-incubation) were added to the cells, and cells were cultured for a further 24 h.
Cell growth was assayed using the WST-1 colorimetric test as described elsewhere (Lyukmanova et al., 2016a,b) . WST-1 (water soluble tetrazolium salt 1; Santa Cruz, Dallas, USA) and 1-m-PMS (1-methoxy-5-methylphenazinium methyl sulfate, Santa Cruz) were added to cell in concentrations of 0.25 mM and 5 μM, respectively, for 1 h, and formation of coloured product was measured in the 440-460 nm spectral range using microplate reader (Uniplan, ZAO Pikon, Moscow, Russia).
The Hoechst 33 342/propidium iodide fluorescent microscopy assay was used to evaluate cytotoxic effects of the studied compounds as described earlier (Ignatova et al., 2009; Efremenko et al., 2012) . Cells were stained with 1 μM Hoechst 33 342 (stains nuclei of all cells) and 0.5 μM propidium iodide (stains nuclei of dead cells) in 96-well microplates and examined using the inverted fluorescence microscope with a long-working distance 20× objective (Axio Observer, Carl Zeiss AG, Oberkochen, Germany). Propidium iodide fluorescence was excited with the 530-585 nm filter and registered with the 615 nm barrier filter. Hoechst 33342 fluorescence was excited with the 359-371 nm filter and registered with the 410 nm barrier filter.
For determination of CDT values, cells were seeded in 96-well cell culture plates and grown for 24 h. Then, WST-1 cell viability test was performed every 8 h.
Confocal fluorescence microscopy
A431, MCF-7, SKBR3 or HT-29 cells were seeded on 13 mm round cover glasses in 24-well plate 1 day before the experiment, in complete medium. Immediately before the experiment, cells were washed once with Hanks solution and incubated in this solution with 1 μM of SLURP-1 labelled by AlexaFluor 647 (SL-1/A647) or by CF ™ 488A (SL-1/ CF488A), or by AlexaFluor555-α-Bgtx (α-Bgtx/A555) for 1 h. After incubation, cells on cover glasses were fixed in 3.7% formaldehyde solution (10 min) and stained with antibodies. Following antibodies were used: AlexaFluor 488 (A488) labelled anti-EGFR IgG (Sony Biotechnology 2364540), rabbit anti-α7-nAChR IgG (Abcam, ab10096), donkey anti-rabbit A488 labelled IgG (Jackson Immunoresearch, and whole rabbit IgG (Thermo Fisher, 10500C). To block non-specific binding, we used 1% BSA in HBSS that was added 5 min before antibodies. In between all steps, cells were washed with HBSS. Stained cells were placed on a microscope slide between two silicon strips of 0.2 mm width (as the spacers for a cover glass), dropped with 50 μL of HBSS, covered with cover glass and imaged with SP2 upright confocal microscope (Leica Microsystems GmbH, Mannheim, Germany). For investigation of the effects of Brefeldin A and recombinant SLURP-1 on expression of endogenous SLURP-1 and α7-nAChRs, A431 cells were grown in complete media, pretreated with 10 μM Brefeldin A for 1 h and then incubated with 1 μM of recombinant SLURP-1. After incubations, cells were fixed; membrane was permeabilized by 0.1% Triton X-100 in PBS; and cells were stained with mouse anti-SLURP-1 (Abcam, ab57569) or rabbit anti-α7-nAChR IgG and goat anti-mouse A488 labelled IgG (Thermo Fisher, A11001) or goat anti-rabbit AlexaFluor 594 labelled IgG (Jackson Immunoresearch, 115-585-003) secondary antibodies. All antibodies were used according to manufacturer recommendations. The specificity of the antibodiesanti-EGFR, anti-α7-nAChR and anti-SLURP-1 -used for immunohistochemistry were confirmed in separate experiments ( Figures S1 and S2 ).
Flow cytometry
For 24 h incubation, 1 nM recombinant SLURP-1 was added directly to A431 cells grown in a 12-well plate. For 1 h incubation, cells were washed twice with HBSS and incubated in HBSS either with or without SLURP-1 for 50 min. After incubation with SLURP-1, cells were washed three times with Versene solution (Paneco, Russia), detached with trypsin/ EDTA for 10 min, pelleted and fixed in 3.7% formaldehyde solution in PBS for 15 min. Fixed cells were permeabilized and quenched for 5 min in PBS solution containing 0.1% Triton X-100, 1% BSA and 50 mM NH 4 Cl. After this step, cells from each well were divided into two tubes, washed in PBS and incubated with either primary antibodies or IgG isotype control (10 mg·L À1 for 45 min at 20°C) in PBS with 1% BSA.
Mouse anti-SLURP-1 and rabbit anti-α7-nAChR primary antibodies, whole mouse and whole rabbit IgG were used. .4 ± 1.1 0.9 ± 0.4 56.9 ± 3.3 3.1 ± 1.9 66.9 ± 2.0 0.3 ± 0.2 71.9 ± 2.7
To quantify expression of functional α7-nAChRs on the cell surface, cells were grown in six-well culture plates in complete medium, detached from wells by Versene solution and stained with α-Bgtx/A555. After that, cells were rinsed twice with PBS, fixed in 2% paraformaldehyde solution in PBS for 15 min and analysed by FC 500 flow cytometer.
Western blot analysis of SLURP-1 secretion
For analysis of SLURP-1 secretion, endogenous SLURP-1 was removed by rinsing A431 cells twice, with complete medium. After that, the cells were incubated with 1 μM recombinant SLURP-1, and the extracellular medium was collected at different time periods. To investigate the role of exocytosis in the SLURP-1 secretion, A431 cells were rinsed twice with a complete medium and grown for 24 h in presence and absence of the 10 μM exocytosis inhibitor Brefeldin A. In these experiments, recombinant SLURP-1 was not added. Total protein concentration in the extracellular media was measured by BCA protein assay (ThermoFisher Scientific, 23227). Then, media were diluted in a loading buffer [120 mM Tris, 20% (v/v) glycerol, 10% (v/v) mercaptoethanol, 4% (w/v) sodium dodecyl sulphate and 0.05% (w/v) bromophenol blue, pH 6.8) and incubated for 5 min at 95°C. Then, lysates were analysed by gel electrophoresis and blotted onto nitrocellulose membranes (Santa-Cruz, USA). After blocking in 3% BSA, the membranes were consequently incubated with primary mouse anti-SLURP-1 antibodies overnight at 4°C and with anti-mouse HRP-conjugated antibodies (Sigma, A3682) for 1 h at room temperature. ECL substrate (Bio-Rad, Hercules, USA) was used for signal detection, and protein bands were visualized using a VersaDoc 4000 imaging system (Biorad). Quantification of protein bands was performed by 'Gel analyser' option of ImageJ software.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Statistical analysis was performed using Mathematica software (Version 7.0, Wolfram Research, Champaign, USA) or GraphPadPrism software (Version 6, GraphPad Software, La Jolla, USA). The data are presented as mean ± SEM.
To determine CDT, cell viability was analysed by WST-1 at 0 h and 24 h of the growth. CDT was calculated by standard curve interpolation option in GraphPadPrism software. The data were measured for six independent samples (n = 6). The WST-1 data concerning cells growth in presence of different compounds (individual or combined application) were normalized to averaged readout from the control wells containing cells without added compounds. The data were measured for six independent titrations (n = 6). Pairwise statistical analysis of the data groups measured with application of one or two compounds was carried out with a Student's two-tailed t-test. P < 0.05 was considered statistically significant. The concentration-effect equation (y = A 0 + (100%-A 0 )/(1 + ([ligand]/EC 50 ))) was fitted to the data measured at several concentrations.
Six independent experiments (n = 6) were performed to accumulate and average flow cytometry data for cells treated and non-treated with SLURP-1. More than 10 000 cells were analysed in each experiment. Multiple comparisons of the non-normalized data groups with the 'control' group were made with ANOVA, followed by post hoc Dunnett's multiple comparisons test. P < 0.05 was considered statistically significant. The post hoc test was only carried out if P < 0.05 was achieved in ANOVA.
Seven independent experiments (n = 7) were performed to obtain Western-blot data about influence of recombinant SLURP-1 on secretion of endogenous SLURP-1. Multiple comparisons of the non-normalized data groups with the 'control' group (0 min) were done using ANOVA followed by post hoc Dunnett's multiple comparisons test. P < 0.05 was considered statistically significant. Post test was only carried out if P < 0.05 was achieved in ANOVA. The kinetics of SLURP-1 secretion were analysed in Mathematica software. The data were normalized to the SLURP-1 level (100%, 0 min) after initial addition of the recombinant protein. 
Materials
Recombinant SLURP-1 and SLURP-2 were produced in E. coli as described previously (Shulepko et al., 2013; Lyukmanova et al., 2014) . The purity and homogeneity of the protein preparations were confirmed by HPLC, MALDI-MS and SDS-PAGE. Disulfide bond formation was confirmed in the reaction with Ellman's reagent (Sigma-Aldrich, St. Louis, USA). The correct spatial structure of the produced proteins was confirmed by NMR spectroscopy. Fluorescent labelling of SLURP-1 with Alexa647 (Life Technologies) or CF ™ 488A
(Sigma Aldrich) was carried out as described in Figure S3 . Gefitinib and α-Bgtx were products of Tocris (Bristol, UK). Мecamylamine, atropine, timolol maleate and Brefeldin A were obtained from Sigma-Aldrich. α-Bgtx/A555 was the product of Life Technologies (B35451).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 (Alexander et al., 2017a,b, c) .
Results

SLURPs affect growth of cancer cell lines of epithelial origin
The effects of recombinant SLURP-1 and SLURP-2 were studied on several human epithelial cancer cell lines (Figure 1 ). Microscopic examination revealed noticeable changes in the density of the epithelial cells exposed to nanomolar concentrations of SLURPs for 24 h, while no obvious alterations in morphology of cells were observed. Examination of cells using the Hoechst/propidium iodide assay showed that the shape of the nuclei was not modified, compared with untreated cells, and the fraction of dead cells was not increased (4 ± 1% of dead cells for both treated and control cells). Quantitative evaluation with the WST-1 colorimetric test revealed that incubation of A431, HT-29, MCF-7 and SKBR3 cells with SLURPs at a concentration of 1 nM and higher during 24 h resulted in a decrease in the number of viable cells to 40-70% of the control value ( Figure 1 ). As there were no signs of cytotoxicity, this decrease can be attributed to the anti-proliferative effect of SLURPs. Thus, in this article, the term 'cell growth' will be used as synonym of the term 'cell proliferation' and vice versa. Analysis of the data showed that the activity of the SLURPs was concentration-dependent, on A431, HT-29, MCF7 and SKBR-3 cells, with EC 50 values ranging from 0.02 to 3.1 nM (Figure 1 , Table 1 ).
Interestingly, SLURP-1 and SLURP-2 demonstrated opposite effects on the lung carcinoma A549 cells. SLURP-1 inhibited proliferation of A549 cells up to~70% of the control (EC 50~1 .8 nM), while SLURP-2 promoted cell growth up to~125% (Figure 1 ). To compare inhibition by SLURPs with the inhibitory effects of snake α-neurotoxins reported previously (Grozio et al., 2008; Zhang et al., 2016) , we studied α-Bgtx on A431, A549, HT-29, MCF-7 and SKBR3 cells (Figure 1) . For all cell lines tested, α-Bgtx was inhibitory with EC 50 values ranging from 0.01 to 1.4 nM ( Table 1) .
Colocalization of SLURP-1 with α7-nAChR in cancer cells
It was reported that SLURP-1, SLURP-2, as well as α-Bgtx target α7-nAChRs (Couturier et al., 1990; Lyukmanova et al., 2016a, b) . To confirm the expression of functional α7-nAChRs on the cell membrane, we incubated samples of the different cell lines with fluorescently labelled α-Bgtx (α-Bgtx/A555) and analysed them by flow cytometry (Figure 2 ). All investigated cell lines expressed some functional α7-nAChRs on their surface but the levels varied between cell lines. The highest level of α-Bgtx/A555 binding sites was found on the surface of A431 and MCF-7 cells, while normal keratinocytes Het-1A, A549, SKBR3 and HT-29 cells demonstrate approximately two-fold lower levels.
To study the SLURP-1 target in the cancer cells, we analysed colocalization of fluorescently labelled SLURP-1 (SL-1/A647) with α7-nAChRs in A431, A549, MCF-7, SKBR3, and HT-29 cells by confocal microscopy. The definite colocalization of SL-1/A647 and α7-nAChRs on the plasma membrane was observed for all cell lines studied (Figure 3) . The SLURP-1 targeting to α7-nAChRs was additionally investigated by co-staining of A431 cells with α-Bgtx/A555 and SL-1/CF488A ( Figure S4 ). The observed colocalization on the plasma membrane revealed that the SLURP-1 targets functional α7 receptors.
The A431 cell line is characterized by overexpression of EGFRs (Anderson et al., 2001) . Recently, the colocalization of α7-nAChRs and EGFRs on the cell membrane of oral and lung cancer cells and intersection of their signalling pathways were proposed (Chernyavsky et al., 2015) . Therefore, to define a receptor that could mediate SLURP-1 effect on A431 cells, we also analysed colocalization of SL-1/A647 with EGFRs. EGFRs were found to be distributed rather uniformly over the plasma membrane of the cells (Figure 3) . As a result of such EGFR distribution, any surface-bound SL-1/A647 was colocalized with EGFRs, but their staining patterns were not correlated, so some cells and membrane regions with high EGFR expression did not bind SL-1/A647 at all. Although these results cannot rule out any interaction between SLURP-1 and EGFRs, they clearly indicate that EGFR alone was not sufficient to bind SLURP-1.
SLURPs inhibit A431 cells growth via various ACh receptors, but not via EGFRs
For a more detailed study of SLURP targets in the epithelial cells, we investigated the antiproliferative effect of these proteins on A431 cells in presence of the specific α7-nAChR inhibitor α-Bgtx and a non-specific nAChR antagonist Figure 3 Colocalization of fluorescently labelled SLURP-1 with α7-nAChRs and EGFRs on epithelial cancer cells. Cells were incubated for 1 h with SL-1/A647, fixed and stained for α7-nAChRs or EGFRs (for A431). Bright field image (first column) and confocal fluorescent images of receptor staining with A488 labelled antibodies (second column), SL-1/A647 distribution (third column) and their overlays (fourth column) are presented. Arrows indicate points on a plasma membrane where SL-1/A647 is colocalized with the α7-nAChRs. Regions of cell membrane with prominent EGFRs staining but with no or low SL-1/A647 membrane binding is marked with arrowheads. Scale bars = 10 μm.
mecamylamine. In addition, to investigate the role of muscarinic receptors, EGFRs and β-adrenoceptors signalling in the antiproliferative action of SLURPs, we used the corresponding inhibitors, atropine, gefitinib and timolol respectively. It should be noted that atropine also shows antagonism at α9-containing nAChRs (Verbitsky et al., 2000) .
To determine optimal concentration of inhibitors, we studied their activity on A431 cells. All inhibitors demonstrated antiproliferative activity. The concentration-effect curves and EC 50 parameters are collected in Figure 1 and Tables 1 and 2 . The effective concentrations of α-Bgtx, gefitinib and timolol we determined here, were close to their expected affinity to α7-nAChRs, EGFRs and β-adrenoceptors respectively. At the same time, the effective concentrations determined for atropine and mecamylamine were lower than their expected affinity to M receptors (~1 nM) and nAChRs (~1 μM), respectively. Increasing the atropine and mecamylamine concentrations up to 10 μM did not enhance their antiproliferative effects ( Figure S5 ). Therefore, for further experiments, we used 10 nM concentration of all inhibitors, which provides saturation of the antiproliferative effects. In addition, 1 μM atropine and 10 μM mecamylamine were also tested.
Mecamylamine and atropine at concentrations from 10 nM to 10 μM reduced the number of viable A431 cells to~80% control (Figures 1 and S5 , Table 2 ). Co-application of 1 nM SLURPs with 10 nM or 10 μM mecamylamine significantly diminished the inhibition of cell growth by the SLURPs (Figures 4 and S5) . At the same time, coapplication of 1 nM SLURPs with 10 nM or 1 μM atropine significantly diminished the antiproliferative action of SLURP-2, while it did not affect the activity of SLURP-1 (Figures 4 and S5) . Taking into account the previously determined pharmacological profiles of SLURPs (Lyukmanova et al., 2016a,b) , we could conclude that antiproliferative action of SLURP-1 on A431 cells was mediated by signalling through α7-nAChRs, but different subtypes of nAChRs and M receptors could be involved in the actions of SLURP-2.
The blockade of β-adrenoceptors by timolol at concentrations ≥1 nM also reduced the number of viable A431 cells tõ 80% of control ( Figure 1 , Table 2 ) and did not significantly influence the antiproliferative activity of SLURPs (Figure 4) . These results indicate that β-adrenoceptors are not involved in the signalling cascades that are responsible for the effects of SLURPs on A431 cells.
In accordance with previously published data (Lin et al., 2010) , we observed significant inhibition of A431 cells growth by gefitinib at concentrations ≥10 nM (up to~65%, Figure 1 , Table 2 ). Co-application of 10 nM gefitinib with 1 nM SLURPs resulted in an additive effect. Incubation during 24 h led to a reduction in the number of viable cells up tõ 50%, while individual compounds decreased the number of viable cells only by 30-35% (Figure 4) . The observed 50% effect corresponds to almost complete inhibition of A431 cell growth as, in our conditions, the doubling time of A431 cells
Figure 4
Effects of SLURP-1 and SLURP-2 and their co-application with mecamylamine (Mec), atropine, timolol, α-Bgtx and gefitinib on the growth of A431 cells (% of control, n = 6, mean ± SEM). The control wells did not contain any added compounds. Concentrations of SLURP-1 or SLURP-2 were 1 nM. Concentrations of other inhibitors were 10 nM. *P < 0.05, significantly different as indicated; Student's two-tailed t-test. The effects of co-application of 1 nM SLURPs with 10 μM Mec or 1 μM atropine are shown on Figure S5B .
Table 2
Potencies of a set of inhibitors (gefitinib, mecamylamine, atropine and timolol) on growth of A431 cells was~26 h (Table 1) . Based on these results, it appears that SLURP-1 and SLURP-2 regulate cell proliferation via intracellular signalling pathway(s), which are not connected with direct activation of EGFRs. Application of SLURPs (1 nM) and α-Bgtx (10 nM), and co-application of SLURPs with α-Bgtx resulted in a similar suppression of cell growth (Figure 4) . The observed difference in the action of α-Bgtx and mecamylamine could be connected with the different mode of the interaction with nAChRs (see Discussion). Co-application of SLURP-1 and SLURP-2 also did not increase the inhibitory effects, possibly because of maximization of the nAChR-related effects (Figure 4 ).
Recombinant SLURP-1 down-regulates the expression of α7-nAChRs and induces secretion of endogenous SLURP-1 into extracellular media of A431 cells
To study the effects of recombinant SLURP-1 on the expression of α7-nAChRs and endogenous SLURP-1 in A431 cells, we used flow cytometry. Incubation of A431 cells for 24 h with recombinant SLURP-1 at concentrations of 1 nM and higher, reduced the level of α7-nAChR subunits by~10% ( Figure 5B ). The reduction became more pronounced (up to~2 5%) if the level of functional α7 receptor was assayed using fluorescently labelled α-Bgtx ( Figure 5C) . Surprisingly, the flow cytometry assay disclosed a significant decrease in the level of endogenous SLURP-1, after only 1 h exposure of cells to recombinant SLURP-1 at concentrations of 1 nM and higher (by~30% in average, Figure 5D ).
Analysis of A431 cells treated by recombinant SLURP-1 by confocal microscopy revealed significant changes in the pattern of localization of endogenous SLURP-1. Before treatment, SLURP-1 was predominantly located in the intracellular compartments, although accumulation of the protein on the border of cells was also apparent (Figure 6 , left column, arrows). After treatment with 1 μM recombinant SLURP-1, the staining intensity of intracellular SLURP-1 was dramatically decreased in 1 h (Figure 6 , middle column). We hypothesized that exposure to the recombinant protein induces the secretion of endogenous SLURP-1 from the intracellular depot to the extracellular medium. To confirm this, we incubated A431 cells before application of recombinant SLURP-1 with an inhibitor of exocytosis, Brefeldin A. Under these conditions, no decrease in the intracellular SLURP-1 level was observed ( Figure 6 , right column).
To study the kinetics of SLURP-1 secretion, we measured levels of the extracellular protein during 24 h after addition of 1 μM recombinant SLURP-1 (Figure 7) . A significant increase in extracellular SLURP-1 was observed as early as 1 h of incubation ( Figure 7C ). The kinetic analysis revealed that secretion process had a half-time of about 1 h. Blockade of exocytosis by Brefeldin A abolished SLURP-1 secretion ( Figure 7B ).
Discussion
SLURP-1 and SLURP-2 were considered to be autocrine or paracrine regulators, controlling the growth, differentiation and migration of keratinocytes (Grando, 2008) . According to our data, as presented above (Figure 1 ), SLURP-1 and SLURP-2 can also regulate growth of malignant epithelial cells. All the epithelial cells we studied exhibited functional α7-nAChRs on the membrane (Figure 2) . The α7-nAChR is supposed to be the target of SLURP-1, while other nAChR subtypes and M receptors could also be targeted by SLURP-2 (Lyukmanova et al., 2016a,b) . In line with this, the effect of SLURP-1 on all the epithelial cells we studied was similar. At the same time, the effects of SLURP-2 varied with cells tested. This protein induced significant reduction of the growth of A431, SKBR3, MCF-7 and HT-29 cells, while stimulating proliferation of lung carcinoma A549 cells (Figure 1) . Previously, similarly opposing effects of SLURP-1 and SLURP-2 were Figure 6 The effect of recombinant SLURP-1 (rSLURP-1) on expression and localization of endogenous SLURP-1 and α7-nAChRs in A431 cells. Untreated cells (control), cells incubated with 1 μM rSLURP-1 for 1 h and cells pretreated by 10 μM Brefeldin A and incubated with 1 μM rSLURP-1 for 1 h were permeabilized and stained with either primary anti-α7-nAChR and Alexa-594 labelled secondary antibodies or with primary anti-SLUPR-1 and Alexa-488 labelled secondary antibodies. Confocal fluorescent images of nuclei stained by Hoechst33342, Alexa-488, Alexa-594 and their merge are shown in rows. Arrows show accumulation of endogenous SLURP-1 near plasma membrane. Scale bars = 20 μm.
observed for normal Het-1A keratinocytes (Lyukmanova et al., 2016b) . Probably, the specific effects of SLURP-2 on cell proliferation depend on the particular range of acetylcholine receptors presented by the different cell lines. Nevertheless, with respect to the hypothesis we formulated initially, we could state that antiproliferative activity on epithelial cell lines is a characteristic feature of SLURP-1.
All investigated cell lines exhibited functional α7-nAChRs on their surface (Figures 2 and 3) . At the same time, the observed levels of α7-nAChR expression on the cell membranes were not correlated with the antiproliferative activity of α-Bgtx and SLURP-1. Thus, it appears that regulation of cell growth by SLURP-1 is controlled by intracellular signalling pathways and does not significantly depend on the concentration of functional α7-nAChRs.
A comparison of SLURP-1 antiproliferative activity on cancer cells (Figure 1 ) with that on normal keratinocytes (Lyukmanova et al., 2016a) revealed the existence of a 'pharmacological window' for this protein. Treatment of A431, SKBR3, MCF-7 and HT-29 cells with 1 nM SLURP-1 resulted in significant inhibition of cell growth (up to 50% control), while no significant antiproliferative effect at this concentration was observed on Het-1A keratinocytes (or on A549 cells) (see Figure 1 in Lyukmanova et al., 2016a) . On these two types of cells, the inhibitory effect of SLURP-1 was significant only at 10 nM.
To study the mechanism of SLURPs action on the epithelial cells, we investigated antiproliferative effect of these proteins on epidermoid carcinoma A431 cells in presence of two types of blockers of nAChRs, α-Bgtx and mecamylamine, with different mechanisms of action. α-Bgtx is a competitive specific inhibitor of α7-nAChRs interacting with the orthosteric ligand-binding site in the extracellular domain of the receptor, whereas mecamylamine is a non-competitive inhibitor of all nAChR subtypes probably acting via the transmembrane domain (Bondarenko et al., 2014) . We found that mecamylamine blocked SLURPs activity, while α-Bgtx exhibited an antiproliferative effect similar in magnitude to those of the SLURPs (Figure 4) . It is possible that binding of SLURPs or α-Bgtx to the receptors initiates some similar nAChR-related signal transduction events (Chernyavsky et al., 2010) , while mecamylamine completely blocked nAChR dependent signalling.
Experiments with the specific inhibitors of muscarinic acetylcholine receptors (M receptors) and β-adrenoceptors (atropine and timolol, respectively) on A431 cells (Figure 4) showed that antiproliferative activity of SLURP-1 was independent of these receptors. At the same time, the antiproliferative activity of SLURP-2 could be, at least partly, mediated by signalling from M receptors. Previously, using CHO cells overexpressing different subtypes of human M receptors, we observed allosteric interactions of SLURP-2 with the M 1 and M 3 receptor subtypes (Lyukmanova et al., 2016b) . We suppose that SLURP-2 could directly interact with muscarinic receptors expressed on the surface of epithelial cells, resulting in the activation of additional intracellular signalling cascades. It should be noted that epithelial cells express both types of ACh receptors (nAChRs and M receptors) and the repertoire of these receptors changes during cell development (Grando et al., 2006) . Thus, SLURP-2 could interact with different subtypes of ACh receptors controlling cell growth at different stages of maturation. A431 cells are known to overexpress EGFRs, which stimulate anti-apoptotic pathways leading to growth of tumour cells (Anderson et al., 2001) . Another possible mechanism underlying our results was that cell proliferation could be related to the stimulation of EGFRs by EGF secreted in response to the activation of α7-nAChRs (Schaal and Chellappan, 2014) . However, our results from the confocal microscopy study (Figure 3 ) and experiments with specific inhibitors (Figure 4) showed clearly that the antiproliferative activity of SLURP-1 was mediated by α7-nAChRs but was not connected with EGFRs. Our finding that both SLURPs inhibited proliferation of MCF-7 cells, which express EGFRs in much lower amounts than A431 cells (Anderson et al., 2001) , also excluded EGFRs from the possible targets of the SLURPs.
Comparison of the inhibitory effects of SLURPs on A431 cells with those of gefitinib, an irreversible inhibitor of EGFRs presently used for therapy of tumours connected with activation of these receptors (Zhang, 2016) , showed a higher potency of SLURPs. Both SLURPs induced significant antiproliferative effect at 1 nM concentration, while gefitinib demonstrated a similar effect at 10 nM concentration (Figure 1 ). Co-application of gefitinib and SLURPs resulted in an additive inhibition of cell proliferation and almost completely prevented growth of A431 cells during 24 h (Figure 4 ). These findings suggest that inhibition of the α7-nAChRs by SLURPs does not affect EGFR activity, and in turn, inhibition of EGFRs by gefitinib does not affect the α7-nAChRs activity. Thus, in spite of the possible colocalization of α7-nAChRs and EGFRs in oral and lung cancer cells (Chernyavsky et al., 2015) , there was no evidence for interactions between nAChRs and EGFRs, in terms of pro-proliferative signalling, in A431 cells.
The endpoints of intracellular signalling events induced by nAChR ligands, such as SLURP-1, in keratinocytes were proposed to be the regulation of expression of a number of genes that finally caused the observed changes in proliferation (Chernyavsky et al., 2010) . On the other hand, the upregulation of α7-nAChRs expression in human lung cancer (Fu et al., 2015) and down-regulation of SLURP-1 expression in colon and lung cancers (Pettersson et al., 2009; Russo et al., 2012) were observed upon treatment with nicotine. Moreover, silencing of the lynx1 gene, coding a modulator of different subtypes of nAChRs (Lyukmanova et al., 2011) expressed at the protein level in the lung (Thomsen et al., 2014) , increases A549 cell growth (Fu et al., 2015) . These data allowed us to hypothesize that the exposure of epithelial cancer cells to recombinant SLURP-1 also could affect expression of proteins involved in nAChR signalling. Indeed, we observed a decrease in the expression of functional α7-nAChRs after incubation of A431 cells with recombinant SLURP-1 during 24 h ( Figure 5) .
A short incubation of A431 cells with recombinant SLURP-1 induced an avalanche-like secretion of the endogenous protein from intracellular depots (Figures 5 and 6 ), achieving maximal extracellular concentration in~4 h ( Figure 7C ). This secretion involves the mechanisms of exocytosis (Figures 6 and 7B ). These data illustrate the previously proposed autocrine/paracrine mode of SLURPs signalling in the epithelium (Grando, 2008; Chernyavsky et al., 2012) and reveal a positive feedback mechanism. This means that increased extracellular concentrations of SLURP-1 stimulate the cells to release their own signalling protein and thus increase the transmission of the signal to the neighbouring cells (Figure 8 ). This process was controlled by the SLURP-1/α7-nAChR interaction on the plasma membrane.
The antiproliferative activity of SLURP-1 and SLURP-2 on epithelial cancer cells was similar to the activity of the snake toxin α-Bgtx (Figure 1 ). All these proteins share a homologous 'three-finger' β-structural fold and, at low concentrations, 1-10 nM, significantly reduce the number of viable cells (except for the A549 cells). At the same time, the snake toxins usually irreversibly block the muscular and α7 neuronal nAChRs and therefore are highly toxic and could not be used for systemic cancer treatment. In contrast, the human Ly6/uPAR proteins bind to the nAChRs reversibly and can be classified as modulators, but not as inhibitors or blockers of the receptors (Lyukmanova et al., 2011) . It is highly likely that these proteins expressed by human epithelial cells would have lower immunogenicity and systemic toxicity when administered to patients. Clearly, further studies are needed, but if so, SLURPs can be considered as promising natural therapeutic agents, capable of controlling the growth of epithelial cancer cells.
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https://doi.org/10.1111/bph.14194 Figure S1 Analysis of anti-SLURP-1 and anti-α7-nAChR antibody specificity for immunohistochemistry. HEK-293 T cells, that do not express either slurp-1 or α7-nAChR genes (confirmed by qPCR analysis), and А431 cells, which possess both genes, were grown on glasses in 24-well cell culture plates (2.5x10 4 cells per well) in complete media for 24 hours. Then, cells were fixed in 4% PFA solution for 10 minutes at room temperature and permeabilized by 0.05% Triton X100 for 1 minute. After that, cells were incubated with rabbit anti-SLURP-1 (central panel) or rabbit anti-α7-nAChR (right panel) antibody in PBS + 1% BSA for 1 hour. Then cells were washed twice and incubated with goat anti-rabbit Alexa-488 labeled secondary antibody for 45 minutes. Cells, incubated only with secondary antibodies were used as negative control (leftpanel). After incubation, cells were washed twice, embedded in mowiol-DABCO and observed under x60 oil-immersion objective of Nikon T2000E confocal microscope (scale =30 μm). Cell nuclei are stained by Hoechst33342. Figure S2 Analysis of anti-EGFR antibody specificity for immunohistochemistry. MCF7 cells, which do not express EGFR, and A431 cells, which overexpress EGFR (Anderson et al., ) , were grown on glasses in 24-well cell culture plates (2,5x104 cells per well) in complete media for 24 hours. Then, cells were fixed in 4% PFA solution for 10 minutes at room temperature and permeabilized by 0.05% Triton X100 for 1 minute. After that, cells were incubated with rabbit anti-EGFR antibody (right panel) in PBS + 1% BSA for 1 hour. Then cells were washed twice and incubated with goat anti-rabbit Alexa-488 labeled secondary antibody for 45 minutes. Cells, incubated only with secondary antibodies were used as negative control (left panel). After incubation cells were washed twice, embedded in mowiol-DABCO and observed under x60 oilimmersion objective of Nikon T2000E confocal microscope (scale = 30 μm). Cell nuclei are stained by Hoechst33342. Figure S3 Purification of the Alexa647 (A) and CFTM488A (B) labeled SLURP-1 by HPLC. Figure S4 Colocalization of fluorescently labeled SLURP-1 (green) with fluorescently labeled α-Bgtx (red) on the plasma membrane of A431 cells. Scale bar =10 μm. with Mec (10 μM) and atropine (1 μM) on A431 cells growth. Control wells did not contain any added compounds. Concentrations of SLURP-1 or SLURP-2 were 1 nM. Data presented as % of control (n = 6, mean ± SEM). * (P < 0.05) indicates the significant difference between groups calculated by two-tailed t-test.
